Table 1 |
||||||||
|
Description of patients and controls |
||||||||
|
RA |
OA |
ReA |
PsA |
AS |
SSc |
SLE |
Control |
|
|
|
||||||||
|
Number |
98 |
58 |
13 |
30 |
30 |
40 |
56 |
97 |
|
Gender (F:M) |
72:26 |
29:29 |
5:8 |
19:11 |
5:25 |
27:13 |
48:8 |
64:33 |
|
Age * (years) |
55 (23-85) |
56 (36-65) |
29 (17-60) |
48 (23-70) |
41 (22-75) |
54 (16-77) |
42 (17-75) |
45 (23-74) |
|
Disease duration (years) |
7.9 (0.8-39) |
Not available |
0.04 (0-0.19) |
6.3 (1.7-23.3) |
15.6 (0.2-55.2) |
1.5 (0.5-19) |
5.0 (0.35) |
Not applicable |
|
COMP-C3b (AU) |
0.42 (0.19-1.19) |
0.58 (0.27-1.36) |
0.74 (0.38-1.14) |
0.31 (0.19-0.92) |
0.33 (0.18-0.51) |
0.76 (0.15-1.43) |
0.50 (0.27-0.85) |
0.20 (0.09-0.83) |
|
COMP (U/L) |
9.1 (3.3-24.4) |
11.2 (6.4-22.1) |
8.9 (4.4-11.2) |
8.2 (4.1-15.3) |
6.8 (3.4-12.4) |
10.5 (2.3-29.0) |
5.6 (3.0-13.3) |
7.0 (3.2-12.1) |
|
CRP (mg/L) |
15.5 (0-126) |
< 5 (< 5-15) |
Not determined |
9.3 (1-205) |
7.9 (0-65) |
12 (0.6-91) |
Not determined |
Not determined |
|
ESR (mm/h) |
29 (2-110) |
6 (1-35) |
48 (2-100) |
18 (4-95) |
14 (2-64) |
18 (2-90) |
Not determined |
Not determined |
|
TNF-α inhibitor infliximab/etanercept/adalimumab |
98/0/0 |
22/6/2 |
9/15/6 |
|||||
|
|
||||||||
|
*Values denote median and range, except for gender and tumor necrosis factor (TNF)-α inhibitor. AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; OA, osteoarthritis; ReA, reactive arthritis; SLE, systemic lupus erythematosus SSc, systemic sclerosis. |
||||||||
|
Happonen et al. Arthritis Research & Therapy 2012 14:R15 doi:10.1186/ar3694 |
||||||||
